Progesterone-induced blocking factor activates STAT6 via binding to a novel IL-4 receptor

Area of Science:

• Immunology
• Molecular Biology
• Cell Signaling

Background:

• Progesterone-induced blocking factor (PIBF) is known to promote Th2-dominant cytokine production.
• The precise molecular mechanisms underlying PIBF's signaling are not fully understood.

Purpose of the Study:

• To elucidate the signaling pathway activated by PIBF, focusing on STAT6 activation and its interaction with the IL-4 receptor (IL-4R).

Main Methods:

• Western blotting and electrophoretic mobility shift assay (EMSA) to assess protein phosphorylation and nuclear translocation.
• Small interfering RNA (siRNA) to silence STAT6.
• Antibody blocking of IL-4R and IL-13R.
• Confocal microscopy for receptor colocalization and cocapping.
• Phosphatidylinositol-specific phospholipase C (PIPLC) digestion.

Main Results:

• PIBF treatment led to STAT6 phosphorylation and nuclear translocation, while inhibiting STAT4 phosphorylation.
• Silencing STAT6 reduced PIBF's cytokine effects.
• Blocking IL-4R, but not IL-13R, abolished PIBF-induced STAT6 activation.
• PIBF activated SOCS3 and inhibited SOCS1 activation, effects counteracted by IL-4R blockade.
• PIBF receptor and IL-4R alpha-chain colocalized and cocapped, suggesting a complex.
• PIBF's STAT6-activating effect was lost after PIPLC digestion, unlike IL-4's effect.

Conclusions:

• PIBF signaling involves a novel IL-4R complex comprising the IL-4R alpha-chain and a GPI-anchored PIBF receptor.
• This interaction facilitates PIBF-induced STAT6 pathway activation and subsequent Th2 cytokine production.
• The findings reveal a new mechanism for immune modulation by PIBF.